In January, an FDA Advisory Committee recommended approval of Titan Pharmaceuticals’ lead product, Probuphine, the first long-acting form of buprenorphine delivered through an implant, as maintenance treatment for opioid addiction. Probuphine uses Titan’s ProNeura long-acting subdermal implant technology. On 19 February, the decision date was delayed until 27 May. Separately, Titan requested a pre-IND meeting for its Parkinson’s disease therapy and recently added a candidate
23 Feb 2016
PDUFA date extended to May 2016
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
PDUFA date extended to May 2016
Titan Pharmaceuticals, Inc. (TTNP:NAS) | 0 0 0.0%
- Published:
23 Feb 2016 -
Author:
Beth Senko -
Pages:
2
In January, an FDA Advisory Committee recommended approval of Titan Pharmaceuticals’ lead product, Probuphine, the first long-acting form of buprenorphine delivered through an implant, as maintenance treatment for opioid addiction. Probuphine uses Titan’s ProNeura long-acting subdermal implant technology. On 19 February, the decision date was delayed until 27 May. Separately, Titan requested a pre-IND meeting for its Parkinson’s disease therapy and recently added a candidate